Beth Mole is a Senior Health Reporter at Ars Technica. With a Ph.D. in microbiology and over a decade of experience, she specializes in infectious diseases, public health, and microbes, often exploring themes related to health and wellness, medicine, and healthcare. Her work has been featured in numerous reputable publications, including WIRED, Nature, and Science News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Beth Mole's coverage is heavily focused on healthcare and pharmaceuticals, with a significant emphasis on citing data, government announcements, and breaking news. Her articles often touch upon topics such as the pharmaceutical industry, FDA regulations, AI in healthcare, public health issues, and scientific developments.
Given her extensive coverage of healthcare-related topics with an emphasis on citing data and government announcements, Beth would likely be interested in receiving pitches from experts who can provide insightful analysis backed by credible data. Additionally, individuals or organizations involved in groundbreaking scientific research or those closely following regulatory changes within the healthcare sector may also capture her attention.
Considering that Beth focuses on national (United States) content but covers global health topics like MDMA therapy for PTSD treatment evaluated by the FDA as well as antibiotic resistance research; she may also consider perspectives from international experts whose insights have implications beyond U.S. borders.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Beth Mole
The departure comes amid turmoil in Kennedy's Make America Healthy Again movement.
By: Beth Mole
Personalized mRNA vaccines against melanoma—the deadliest form of skin cancer—reduced the risk of death or recurrence by 42 percent compared to standard treatment in a late-stage trial, pharmaceutical partners Merck and Moderna announced Thursday. The results are a significant advance in melanoma treatment;…
Trust is slow to build and quick to lose," board chair Jack Leslie said.
10 pts At a recent meeting of the board that oversees the National Institutes of Health's Clinical Center Research Hospital, chair Jack Leslie opened with cheerful introductions and gregarious chatter—then diverted from the agenda of the regularly scheduled meeting. He spent the next six minutes delivering a pointed…
Pregnant female worm releases first-stage larvae. After two months of discomfort, a man in South Korea went to an eye clinic where doctors pulled 11 living, wriggling worms from his eyes.
By: Beth Mole
6 pts After two months of discomfort, a man in South Korea went to an eye clinic where doctors pulled 11 living, wriggling worms from his eyes. They apparently made the most of their time on the man's peepers; at the time of extraction, many of the female worms were pregnant. The man narrowly avoided having them spew…
By: Beth Mole
International travel used to be the main risk of measles cases in the US—not anymore.
By: Beth Mole
Since measles was declared eliminated in the US in 2000, the country's occasional cases have come mainly from international travelers—visitors from far-flung places where the virus still spreads freely — or unvaccinated US residents who return from abroad with a highly infectious souvenir. But as…
Anti-vaccine Health Secretary Robert F. Kennedy has unilaterally passed a rule that will allow specialty pharmacies to sell six specific peptide drugs, overruling scientists at the Food and Drug Administration.
By: Beth Mole
7 pts Anti-vaccine Health Secretary Robert F. Kennedy has unilaterally passed a rule that will allow specialty pharmacies to sell six specific peptide drugs, overruling scientists at the Food and Drug Administration. The peptides are popular among members of Kennedy's Make America Health Again movement and many…
